"We are pleased to put this matter behind us and continue to concentrate on our clinical programs and strategic growth initiatives," said Bob Butchofsky, President and Chief Executive Officer of QLT. "We believe that this agreement fairly resolves our dispute and serves to recognize the critically important contributions made by MGH in the development of Visudyne."
About QLT
QLT Inc. is a pharmaceutical company dedicated to the development and commercialization of innovative therapies for the eye. We are focused on our commercial product Visudyne(R) for the treatment of wet-AMD, and the development of drugs to be delivered in our proprietary punctal plug devices. For more information, visit our website at www.qltinc.com.
Visudyne is a registered trademark of Novartis AG.
QLT Inc. is listed on The NASDAQ Stock Market under the trading symbol "QLTI" and on the
For further information: QLT Inc., Vancouver, Canada, Karen Peterson, Telephone: (604) 707-7000 or 1-800-663-5486, Fax: (604) 707-7001, [email protected]; The Trout Group Investor Relations Contact: New York, USA, Christine Yang, Telephone: (646) 378-2929, [email protected]; or Marcy Nanus, Telephone: (646) 378-2927, [email protected]
Share this article